Axsome Therapeutics, Inc.
AXSM
Pozycja w akcjach
#2360
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Cena akcji
$158.36
Kapitalizacja rynkowa
$8.29B
Zmiana (1 dzień)
-0.77%
Zmiana (1 rok)
20.52%
Kraj
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategoria
Healthcare
Przychody dla Axsome Therapeutics, Inc. (AXSM)
Przychody w Jun 2026 TTM: $776.57M
Według najnowszych raportów finansowych Axsome Therapeutics, Inc., obecny przychód firmy (TTM) wynosi $776.57M. W roku 2023 firma osiągnęła przychód w wysokości $270.60M wzrost w porównaniu do przychodu z roku 2022, który wynosił $50.04M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Axsome Therapeutics, Inc. od 2013 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $776.57M | 101.34% |
| 2024 | $385.69M | 42.53% |
| 2023 | $270.60M | 440.80% |
| 2022 | $50.04M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 1,525.65% |
US
|
|
| $2.23B | 186.90% |
US
|
|
| $15.74B | 1,927.42% |
AU
|
|
| $6.02B | 675.37% |
NL
|
|
| - | - |
CH
|
